Literature DB >> 25701281

Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain.

Gerardo Leyva-Gómez1, Hernán Cortés2, Jonathan J Magaña2, Norberto Leyva-García2, David Quintanar-Guerrero3, Benjamín Florán4.   

Abstract

The absence of a definitive treatment for Parkinson's disease has driven the emerging investigation in the search for novel therapeutic alternatives. At present, the formulation of different drugs on nanoparticles has represented several advantages over conventional treatments. This type of multifunctional carrier, owing to its size and composition, has different interactions in biological systems that can lead to a decrease in ability to cross the blood-brain barrier. Therefore, this review focuses on the latest advances in obtaining nanoparticles for Parkinson's disease and provides an overview of technical aspects in the design of brain drug delivery of nanoparticles and an analysis of surface phenomena, a key aspect in the development of functional nanoparticles for Parkinson's disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25701281     DOI： 10.1016/j.drudis.2015.02.009

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  9 in total

1.  Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy.

Authors:  Prashant Kumar; Yeruva Samrajya Lakshmi; Anand K Kondapi
Journal:  Pharm Res       Date:  2016-12-07       Impact factor: 4.200

Review 2.  Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.

Authors:  Elizabeth S Smith; Joshua E Porterfield; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2019-03-04       Impact factor: 15.470

Review 3.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 4.  Progress, Opportunities, and Challenges of Magneto-Plasmonic Nanoparticles under Remote Magnetic and Light Stimulation for Brain-Tissue and Cellular Regeneration.

Authors:  Muzhaozi Yuan; Mackenzie Caitlin Harnett; Tian-Hao Yan; Elias Georgas; Yi-Xian Qin; Hong-Cai Zhou; Ya Wang
Journal:  Nanomaterials (Basel)       Date:  2022-06-29       Impact factor: 5.719

5.  Biodegradable Nanoparticles Loaded with Levodopa and Curcumin for Treatment of Parkinson's Disease.

Authors:  Bassam Felipe Mogharbel; Marco André Cardoso; Ana Carolina Irioda; Priscila Elias Ferreira Stricker; Robson Camilotti Slompo; Julia Maurer Appel; Nathalia Barth de Oliveira; Maiara Carolina Perussolo; Claudia Sayuri Saçaki; Nadia Nascimento da Rosa; Dilcele Silva Moreira Dziedzic; Christophe Travelet; Sami Halila; Redouane Borsali; Katherine Athayde Teixeira de Carvalho
Journal:  Molecules       Date:  2022-04-28       Impact factor: 4.927

6.  Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.

Authors:  Chenchen Bi; Aiping Wang; Yongchao Chu; Sha Liu; Hongjie Mu; Wanhui Liu; Zimei Wu; Kaoxiang Sun; Youxin Li
Journal:  Int J Nanomedicine       Date:  2016-12-07

Review 7.  Repositioning of drugs for Parkinson's disease and pharmaceutical nanotechnology tools for their optimization.

Authors:  Héctor Hernández-Parra; Hernán Cortés; José Arturo Avalos-Fuentes; María Del Prado-Audelo; Benjamín Florán; Gerardo Leyva-Gómez; Javad Sharifi-Rad; William C Cho
Journal:  J Nanobiotechnology       Date:  2022-09-15       Impact factor: 9.429

Review 8.  Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases.

Authors:  Miguel Chin-Chan; Juliana Navarro-Yepes; Betzabet Quintanilla-Vega
Journal:  Front Cell Neurosci       Date:  2015-04-10       Impact factor: 5.505

9.  In situ apolipoprotein E-enriched corona guides dihydroartemisinin-decorating nanoparticles towards LDLr-mediated tumor-homing chemotherapy.

Authors:  Zhenbao Li; Jiaojiao Zhu; Yongqi Wang; Mei Zhou; Dan Li; Shunzhe Zheng; LiLi Yin; Cong Luo; Huicong Zhang; Lu Zhong; Wei Li; Jian Wang; Shuangying Gui; Biao Cai; Yongjun Wang; Jin Sun
Journal:  Asian J Pharm Sci       Date:  2019-07-05       Impact factor: 6.598
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.